AU2015222913B2 - JAK1 inhibitors for the treatment of myelodysplastic syndromes - Google Patents
JAK1 inhibitors for the treatment of myelodysplastic syndromes Download PDFInfo
- Publication number
- AU2015222913B2 AU2015222913B2 AU2015222913A AU2015222913A AU2015222913B2 AU 2015222913 B2 AU2015222913 B2 AU 2015222913B2 AU 2015222913 A AU2015222913 A AU 2015222913A AU 2015222913 A AU2015222913 A AU 2015222913A AU 2015222913 B2 AU2015222913 B2 AU 2015222913B2
- Authority
- AU
- Australia
- Prior art keywords
- pyrimidin
- pyrrolo
- pyrazol
- trifluoromethyl
- acetonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DAVCOHVWAJXWPB-XBXARRHUSA-N C/C=C(/C1N=CN=C2NC=CC12)\C=C Chemical compound C/C=C(/C1N=CN=C2NC=CC12)\C=C DAVCOHVWAJXWPB-XBXARRHUSA-N 0.000 description 1
- JKMHKJRBEGMJBK-OYRHEFFESA-N CC(C)(c1cc(O[C@H](CC2)CC[C@H]2N(C2)CC2(CC#N)[n]2ncc(-c3c(cc[nH]4)c4ncn3)c2)nc(C(F)(F)F)c1)O Chemical compound CC(C)(c1cc(O[C@H](CC2)CC[C@H]2N(C2)CC2(CC#N)[n]2ncc(-c3c(cc[nH]4)c4ncn3)c2)nc(C(F)(F)F)c1)O JKMHKJRBEGMJBK-OYRHEFFESA-N 0.000 description 1
- JVOBWWADKXBUDY-AWEZNQCLSA-N C[C@@H](C(F)(F)F)NC(c(c(F)c1)cc(F)c1N(C1)CC1(CC#C)[n]1ncc(-c2c(cc[nH]3)c3ncn2)c1)=O Chemical compound C[C@@H](C(F)(F)F)NC(c(c(F)c1)cc(F)c1N(C1)CC1(CC#C)[n]1ncc(-c2c(cc[nH]3)c3ncn2)c1)=O JVOBWWADKXBUDY-AWEZNQCLSA-N 0.000 description 1
- CDVDPTDKMZZTCV-BGYRXZFFSA-N Cc1cc(O[C@H](CC2)CC[C@H]2N(C2)CC2(CC#N)[n]2ncc(-c3c(cc[nH]4)c4ncn3)c2)nc(C(F)(F)F)c1 Chemical compound Cc1cc(O[C@H](CC2)CC[C@H]2N(C2)CC2(CC#N)[n]2ncc(-c3c(cc[nH]4)c4ncn3)c2)nc(C(F)(F)F)c1 CDVDPTDKMZZTCV-BGYRXZFFSA-N 0.000 description 1
- VQDFOOLMNPPTBD-UHFFFAOYSA-N N#CCC(CN(CC1)CCN1C(c(c(F)c1)ccc1C#N)=O)[n]1ncc(-c2c(cc[nH]3)c3ncn2)c1 Chemical compound N#CCC(CN(CC1)CCN1C(c(c(F)c1)ccc1C#N)=O)[n]1ncc(-c2c(cc[nH]3)c3ncn2)c1 VQDFOOLMNPPTBD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946124P | 2014-02-28 | 2014-02-28 | |
| US61/946,124 | 2014-02-28 | ||
| PCT/US2015/017963 WO2015131031A1 (en) | 2014-02-28 | 2015-02-27 | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015222913A1 AU2015222913A1 (en) | 2016-09-29 |
| AU2015222913B2 true AU2015222913B2 (en) | 2019-12-12 |
Family
ID=52693052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015222913A Active AU2015222913B2 (en) | 2014-02-28 | 2015-02-27 | JAK1 inhibitors for the treatment of myelodysplastic syndromes |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US20150246046A1 (enExample) |
| EP (1) | EP3110409B1 (enExample) |
| JP (1) | JP6576941B2 (enExample) |
| KR (1) | KR20160136323A (enExample) |
| CN (2) | CN106456773A (enExample) |
| AU (1) | AU2015222913B2 (enExample) |
| CA (1) | CA2940659C (enExample) |
| CL (1) | CL2016002144A1 (enExample) |
| CR (1) | CR20160449A (enExample) |
| CY (1) | CY1120857T1 (enExample) |
| DK (1) | DK3110409T3 (enExample) |
| EA (1) | EA201691745A1 (enExample) |
| ES (1) | ES2688553T3 (enExample) |
| HR (1) | HRP20181661T1 (enExample) |
| HU (1) | HUE041456T2 (enExample) |
| IL (1) | IL247475B (enExample) |
| LT (1) | LT3110409T (enExample) |
| MX (1) | MX372939B (enExample) |
| MY (1) | MY185392A (enExample) |
| PE (1) | PE20161388A1 (enExample) |
| PL (1) | PL3110409T3 (enExample) |
| PT (1) | PT3110409T (enExample) |
| RS (1) | RS57723B1 (enExample) |
| SG (2) | SG11201607083VA (enExample) |
| SI (1) | SI3110409T1 (enExample) |
| SM (1) | SMT201800551T1 (enExample) |
| UA (1) | UA121857C2 (enExample) |
| WO (1) | WO2015131031A1 (enExample) |
| ZA (1) | ZA201606610B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| BRPI1012108B8 (pt) | 2009-05-22 | 2021-05-25 | Incyte Corp | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico |
| CA2792508C (en) | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| EA202091303A3 (ru) | 2010-05-21 | 2021-05-31 | Инсайт Холдингс Корпорейшн | Композиция ингибитора jak для местного применения |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| CA2888816A1 (en) | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| KR102242077B1 (ko) | 2012-11-15 | 2021-04-20 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| TWI662030B (zh) | 2013-01-15 | 2019-06-11 | 英塞特控股公司 | 適用作ｐｉｍ激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物 |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| CR20190156A (es) | 2013-05-17 | 2019-05-16 | Incyte Corp | Derivados de bipirazol como inhibidores jak |
| MX376856B (es) | 2013-08-07 | 2025-03-07 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| CA3158254C (en) | 2014-04-08 | 2024-05-21 | Incyte Corporation | Treatment of b-cell malignancies by a combination jak and pi3k inhibitors |
| SG11201609016VA (en) | 2014-04-30 | 2016-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| US20190183900A1 (en) * | 2016-03-09 | 2019-06-20 | University Of Ulsan Foundation For Industry Cooperation | Composition for proliferation, differentiation promotion, or senescence inhibition of stem cells, containing jak1 inhibitor as active ingredient |
| KR101934107B1 (ko) * | 2016-12-15 | 2018-12-31 | 가톨릭대학교산학협력단 | 골수형성이상 증후군 환자의 저메틸화 제제 치료 반응성 및 생존 예후 예측용 조성물 |
| EP3572415B1 (en) | 2017-01-23 | 2024-03-06 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Jak kinase inhibitor and preparation method and use thereof |
| CN109867676B (zh) * | 2017-12-01 | 2020-10-30 | 北京普祺医药科技有限公司 | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| MD3746429T2 (ro) | 2018-01-30 | 2022-08-31 | Incyte Corp | Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă) |
| WO2019152875A1 (en) | 2018-02-01 | 2019-08-08 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use and manufacture |
| CA3091339A1 (en) * | 2018-02-16 | 2019-08-22 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of cytokine-related disorders |
| WO2019191679A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Biomarkers for inflammatory skin disease |
| KR20260080448A (ko) | 2018-03-30 | 2026-06-02 | 인사이트 코포레이션 | Jak 억제제를 사용하는 화농성 한선염의 치료 |
| CN112567247A (zh) | 2018-04-13 | 2021-03-26 | 因赛特公司 | 用于移植物抗宿主病的生物标志物 |
| IL278889B2 (en) | 2018-06-01 | 2025-11-01 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| CA3117678A1 (en) * | 2018-10-31 | 2020-05-07 | Stemline Therapeutics, Inc. | Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents |
| KR20210109522A (ko) | 2018-10-31 | 2021-09-06 | 인사이트 코포레이션 | 혈액 질환의 치료를 위한 병용 요법 |
| CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
| UA130579C2 (uk) * | 2019-03-05 | 2026-03-25 | Інсайт Корпорейшн | Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| US12360120B2 (en) | 2019-10-10 | 2025-07-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| WO2021072116A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| CN111358791A (zh) * | 2020-03-13 | 2020-07-03 | 深圳百奥捷生物科技有限公司 | Jak/stat信号通路磷酸盐抑制剂在制备治疗dba疾病的药物中的应用 |
| SI4157831T1 (sl) | 2020-06-02 | 2025-02-28 | Incyte Corporation | Postopki za pripravo zaviralca jak1 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| IL303238A (en) | 2020-12-08 | 2023-07-01 | Incyte Corp | Jak1 pathway inhibitors for the treatment of vitiligo |
| WO2022152902A1 (en) * | 2021-01-18 | 2022-07-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| AU2022270072A1 (en) | 2021-05-03 | 2023-11-02 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of prurigo nodularis |
| CN121399112A (zh) * | 2023-04-27 | 2026-01-23 | 维泰瑞隆有限公司 | Sarm1调节剂、其制备和用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012071612A1 (en) * | 2010-12-03 | 2012-06-07 | Ym Biosciences Australia Pty Ltd | Treatment of jak2-mediated conditions |
| US20140004516A1 (en) * | 2012-06-12 | 2014-01-02 | Dana-Farber Cancer Institute, Inc. | Methods of Predicting Resistance to JAK Inhibitor Therapy |
| WO2014071031A1 (en) * | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| WO2014186706A1 (en) * | 2013-05-17 | 2014-11-20 | Incyte Corporation | Bipyrazole derivatives as jak inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| CN100391958C (zh) | 2001-09-19 | 2008-06-04 | 安万特医药股份有限公司 | 化合物 |
| PT1441737E (pt) | 2001-10-30 | 2006-12-29 | Dana Farber Cancer Inst Inc | Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3 |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| RU2007123675A (ru) | 2004-11-24 | 2008-12-27 | Новартис АГ (CH) | Комбинации ингибиторов jak |
| AR053992A1 (es) | 2004-12-22 | 2007-05-30 | Astrazeneca Ab | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. |
| HUE028588T2 (hu) * | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| NZ596479A (en) * | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| CA2792508C (en) * | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| ES2536415T3 (es) * | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| US8691807B2 (en) * | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
-
2015
- 2015-02-27 SG SG11201607083VA patent/SG11201607083VA/en unknown
- 2015-02-27 PT PT15710994T patent/PT3110409T/pt unknown
- 2015-02-27 EP EP15710994.3A patent/EP3110409B1/en active Active
- 2015-02-27 PE PE2016001538A patent/PE20161388A1/es unknown
- 2015-02-27 WO PCT/US2015/017963 patent/WO2015131031A1/en not_active Ceased
- 2015-02-27 LT LTEP15710994.3T patent/LT3110409T/lt unknown
- 2015-02-27 UA UAA201609815A patent/UA121857C2/uk unknown
- 2015-02-27 JP JP2016554471A patent/JP6576941B2/ja active Active
- 2015-02-27 MY MYPI2016001574A patent/MY185392A/en unknown
- 2015-02-27 RS RS20181194A patent/RS57723B1/sr unknown
- 2015-02-27 US US14/633,605 patent/US20150246046A1/en not_active Abandoned
- 2015-02-27 CN CN201580017178.XA patent/CN106456773A/zh active Pending
- 2015-02-27 SG SG10201807952PA patent/SG10201807952PA/en unknown
- 2015-02-27 KR KR1020167026668A patent/KR20160136323A/ko not_active Ceased
- 2015-02-27 ES ES15710994.3T patent/ES2688553T3/es active Active
- 2015-02-27 CN CN202010986614.7A patent/CN112494652A/zh active Pending
- 2015-02-27 HR HRP20181661TT patent/HRP20181661T1/hr unknown
- 2015-02-27 CA CA2940659A patent/CA2940659C/en active Active
- 2015-02-27 HU HUE15710994A patent/HUE041456T2/hu unknown
- 2015-02-27 PL PL15710994T patent/PL3110409T3/pl unknown
- 2015-02-27 EA EA201691745A patent/EA201691745A1/ru unknown
- 2015-02-27 SM SM20180551T patent/SMT201800551T1/it unknown
- 2015-02-27 CR CR20160449A patent/CR20160449A/es unknown
- 2015-02-27 DK DK15710994.3T patent/DK3110409T3/en active
- 2015-02-27 SI SI201530368T patent/SI3110409T1/sl unknown
- 2015-02-27 AU AU2015222913A patent/AU2015222913B2/en active Active
- 2015-02-27 MX MX2016011103A patent/MX372939B/es active IP Right Grant
-
2016
- 2016-08-24 CL CL2016002144A patent/CL2016002144A1/es unknown
- 2016-08-25 IL IL247475A patent/IL247475B/en active IP Right Grant
- 2016-09-23 ZA ZA2016/06610A patent/ZA201606610B/en unknown
-
2018
- 2018-05-15 US US15/980,052 patent/US20190111058A1/en not_active Abandoned
- 2018-11-13 CY CY181101196T patent/CY1120857T1/el unknown
-
2020
- 2020-04-03 US US16/839,972 patent/US20210069193A1/en not_active Abandoned
-
2021
- 2021-12-20 US US17/556,374 patent/US20220378791A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012071612A1 (en) * | 2010-12-03 | 2012-06-07 | Ym Biosciences Australia Pty Ltd | Treatment of jak2-mediated conditions |
| US20140004516A1 (en) * | 2012-06-12 | 2014-01-02 | Dana-Farber Cancer Institute, Inc. | Methods of Predicting Resistance to JAK Inhibitor Therapy |
| WO2014071031A1 (en) * | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| WO2014186706A1 (en) * | 2013-05-17 | 2014-11-20 | Incyte Corporation | Bipyrazole derivatives as jak inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3110409T3 (en) | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | |
| US11760744B2 (en) | Fused ring compounds | |
| KR102627097B1 (ko) | Mdm2-p53 억제제로서의 신규 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체 | |
| DK2545045T3 (en) | PIPERIDINE-4-YL-azetidine derivatives AS JAK1 INHIBITORS | |
| CA2839767A1 (en) | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors | |
| CA2818542A1 (en) | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors | |
| CA2814419A1 (en) | Cxcr4 receptor antagonists | |
| JP2013501002A (ja) | Ｓｙｋキナーゼ阻害剤としての化合物および組成物 | |
| CN106478607B (zh) | 取代的杂芳基化合物及其组合物和用途 | |
| BR112018007155B1 (pt) | Novos compostos de espiro[3h-indol-3,2-pirrolidin]-2(1h)-ona e derivados como inibidores de mdm2-p53 | |
| EP3464267B1 (en) | New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors | |
| JP2019501873A (ja) | イミダゾ［４，５−ｃ］キノリン−２−オン化合物及び癌の治療におけるその使用 | |
| US12534479B2 (en) | Triazine compound and composition and use thereof | |
| JP2018527362A (ja) | 置換されたヘテロアリール化合物および使用方法 | |
| EP3691642B1 (en) | [1,6]naphthyridine compounds and derivatives as cdk8/cdk19 inhibitors | |
| CN119546604A (zh) | 作为hpk1抑制剂的吡啶并[3,2-d]嘧啶 | |
| JP2018507236A (ja) | トリアゾロピリジン化合物及びその使用法 | |
| HK1231762A1 (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
| HK1231762B (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
| JP2023503322A (ja) | Ｄｕｘ４発現に関連する疾患を処置するための新規化合物 | |
| NZ724464B2 (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
| BR112016019511B1 (pt) | Uso de inibidores de jak1 para o tratamento de síndromes mielodisplásicas | |
| EA040337B1 (ru) | Ингибиторы jak1 для лечения миелодиспластических синдромов | |
| TW202448895A (zh) | 作為egfr抑制劑之大環胺基吡啶化合物 | |
| HK1245783A1 (en) | Triazolopyridine compounds and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: INCYTE HOLDINGS CORPORATION Free format text: FORMER OWNER(S): INCYTE CORPORATION |